LexaGene Grants Stock Options

LexaGene Grants Stock Options

VANCOUVER, B.C., March 3, 2017 – LexaGene Holdings Inc. (TSX-V: LXG) (the “Company”) announces that it has granted to directors and officers of the Company stock options (the “Options” to purchase a total of 1,675,000 common shares at a price of $0.33 per common share, and 500,000 common shares at a price of $0.363 per common share. The options are exercisable for a 42 month period ending on July 27, 2020 and have been granted in accordance with the terms of the Company’s current stock option plan.

ON BEHALF OF THE BOARD “Jack Regan”
Jack Regan, Chief Executive Officer and Director

For further information, please contact:
Jack Regan, Chief Executive Officer, jackregan@lexagene.com

The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors — including the availability of funds, the results of financing efforts, the success of technology development efforts, the cost to procure critical parts, performance of the instrument, market acceptance of the technology, regulatory acceptance, and licensing issues — that could cause actual results to differ materially from the Company’s expectations as disclosed in the Company’s documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

For Media Inquiries Contact

Gail Winslow

Director, Marketing

978 - 482 - 6237